Advertisement


Roy S. Herbst, MD, PhD, on LUNG-MAP, Circulating Tumor DNA, and Tissue Molecular Analysis

IASLC 2020 World Conference on Lung Cancer in Singapore

Advertisement

Roy S. Herbst, MD, PhD, of Yale University, discusses results from the LUNG-MAP Master Protocol, which support the planned use of circulating tumor DNA for enrollment onto LUNG-MAP substudies, with a positive finding meriting inclusion in study; a negative finding, while considered inconclusive, requires the use of tissue samples (Abstract MA08.10).



Related Videos

Lung Cancer

Roy S. Herbst, MD, PhD, on NSCLC: Osimertinib and Patient-Reported Outcomes

Roy S. Herbst, MD, PhD, of Yale University, discusses two key abstracts from the ADAURA trial: the use of osimertinib as adjuvant therapy for resected EGFR-mutated non–small cell lung cancer; and patient-reported outcomes, which showed a benefit in disease-free survival and maintenance of health-related quality of life in patients with resected stage IB to IIIA disease (Abstracts OA06.04 and OA06.03).

Lung Cancer
Immunotherapy

Justin F. Gainor, MD, on NSCLC: Study Results on Nivolumab vs Ipilimumab, Bemcentinib Plus Pembrolizumab

Justin F. Gainor, MD, of Massachusetts General Hospital, discusses two key phase II studies on non–small cell lung cancer: nivolumab vs nivolumab plus ipilimumab in EGFR-mutant disease and the oral selective AXL inhibitor bemcentinib with pembrolizumab in advanced disease (Abstracts OA01.06 and OA01.07).

Lung Cancer

Jill Feldman: A Determined Cancer Survivor Shares Her Story of a Family Devastated by Lung Cancer

Jill Feldman, a patient advocate who has lost five family members to lung cancer and is herself a 12-year cancer survivor living with EGFR-positive disease, describes her family history of cancer, how she has worked with her physicians for more than a decade to survive her own diagnosis, and the message she would like all oncologists to hear.

Lung Cancer
COVID-19

Fred R. Hirsch, MD, PhD, on Searching for Therapeutic Strategies for Patients With Lung Cancer and COVID-19 Infection

Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, invites his colleagues to enroll their patients in a large prospective study, for which he serves as Principal Investigator. The study is searching for solutions for treating patients with lung cancer who also have the coronavirus, because so many experience an aggressive course of infection.

Lung Cancer

Silvia Novello, MD, PhD, on NSCLC: Pharmacogenomics-Driven vs Standard Adjuvant Chemotherapy

Silvia Novello, MD, PhD, of the University of Turin, discusses phase III results from the ITACA trial, which explored the notion of improving survival by customizing treatment and reducing toxicities for patients with completely resected stage II to IIIA non–small cell lung cancer (Abstract PS01.04).

Advertisement

Advertisement




Advertisement